Cancer mutations and targeted therapies

Selected publications

• Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A.
  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
  (2010) J Clin Invest. Aug 2;120(8):2858-66. doi: 10.1172/JCI37539.
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.
  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
  (2010) Lancet Oncol. Aug;11(8):753-62.
• Siena S. and Bardelli A.
  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
  (2010) J Clin Oncol. Mar 1;28(7):1181-9.
• Di Nicolantonio F, Arena S, Gallicchio and Bardelli A.
  Isogenic mutant human cells: A new tool for personalized cancer medicine.
  (2010) Cell Cycle. Jan 1;9(1):20-1. Epub 2010 Jan 29.
• Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.
  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer.
  (2009) Journal of the National Cancer Institute. Oct 7;101(19):1308-24. Epub 2009 Sep 8. Review.
• Sartore-Bianchi A, Martini M, Molinari M, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena Sand Bardelli A
  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
  (2009) Cancer Res. 1;69(5):1851-7.
• Bleeker FE, Lamba S, Rodolfo M, Scarpa A, Leenstra S, Vandertop WP and Bardelli A
  Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes
  (2009) Human Mutation. Feb;30(2):E451-9.
• Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A and Bardelli A
  IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors
  (2009) Human Mutation. Jan;30(1):7-11.
• Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A
  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
  (2008) Journal of Clinical Oncology. Dec 10;26(35):5705-12.
• Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino M, Fantozzi R, Medico E and Bardelli A
  Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
  (2008) Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dec 30;105(52):20864-9.
• Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Del Grammastro M, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A
  AKT1 (E17K) in human solid tumours.
  (2008) Oncogene. May 26 [Epub ahead of print]
• Arena S, Bardelli A
  Understanding how kinase-targeted therapies work.
  (2008) Cell Cycle. Mar 30;7(11)
• Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A.
  PIK3CA cancer mutations display gender and tissue specificity patterns.
  (2008) Hum Mutat. Feb;29(2):284-8.
• Bleeker FE, Bardelli A.
  Genomic landscapes of cancers: prospects for targeted therapies.
  (2007) Pharmacogenomics. Dec;8(12):1629-33.
• Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A.
  Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.
  (2007) Cancer Res. Sep 15;67(18):8468-76.
• Arena S., Pisacane A., Mazzone, M., Comoglio P.M. and Bardelli A.,
  Genetic targeting the kinase activity of the Met receptor in cancer cells.
  (2007) Proceedings of the National Academy of Sciences of the United States of America (PNAS) vol 104, no.27, 11412-11417.
• Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C, Bardelli A.
  Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma.
  (2007) Cancer Res. Apr 15;67(8):3545-3550.
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.
  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
  (2007) Cancer Res. Mar 15;67(6):2643-8.
• Di Nicolantonio F. and Bardelli A.
  Kinase Mutations in Cancer: "Chinks in the Enemy's Armour ?".
  (2006) Curr Opin Oncol. (1):69-76.
• Polato F., Codegoni A., Fruscio R., Perego P., Mangioni C., Broggini* M., and Bardelli A*.
  PRL-3 phosphatase is implicated in ovarian cancer growth.
  (2005) Clinical Cancer Research. 11(19):6835-9.
  * shared last authorship
• Frattini M., Signoroni S., Pilotti S., Bertario L., Benvenuti S., Zanon C., Bardelli A., and Pierotti M.A.
  Phosphatase protein homologue to tensin expression and phosphatidylinositol-3
  phosphate kinase mutations in colorectal cancer.
  (2005) Cancer Res.; 65(23):11227.
• Parsons W.D.*, Samuels Y.*, Bardelli A.*, Silliman N., Saha S., Markowitz S., Willson J.K., Kinzler K.W., Vogelstein B., and Victor E. Velculescu.
  Mutational Analysis of the Serine/Threonine Kinome In Colorectal Cancers Identifies Alterations In PI3K Pathway Genes.
  * Shared first authorship
  (2005) Nature. Aug 11;436(7052):792.
• Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., and Bardelli A.
  Copy number increase of the epidermal growth factor receptor gene is associated with clinical response of colorectal cancer to anti-EGFR antibody therapy.
  (2005) The LANCET Oncology 6(5):279-86.
• Bardelli A., and Velculescu V.
  Mutational profiling of gene families in cancer.
  (2005) Current Opinion in Genetics and Development, 15(1):5-12.
• Bentires-Alj M., Paez JG, David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., and Neel B.G.
  Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
  (2004) Cancer Res. Dec 15;64(24):8816-20.
• Wang Z. Shen D. Parsons D.W., Bardelli A., Sager J., Szabo S., Ptak J., Silliman N., Peters B.A., Van der Heijden M.S., Parmigiani G., Yan H., Wang T.L., Riggins G., Powell S.M., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E.
  Mutational analysis of the tyrosine phosphatome in colorectal cancers.
  (2004) Science. May 21;304(5674):1164-6.
• Samuels, Y., Wang, Z., Bardelli A., Ptak J., Szabo S., Silliman N., Scott K., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E..
  Mutations of the PIK3CA gene in human cancers.
  (2004) Science,: 304; 554-555
• Bardelli A., Parsons W.D., Silliman N., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E..
  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers.
  (2003) Science, 300:949.
• Bardelli A., Saha, S., Lengauer, C., Velculescu V.E., Kinzler, K.W. and Vogelstein B.
  PRL-3 Expession in metastatic cancers.
  (2003) Clinical Cancer Research, 9,5607-5615.
• Rajagopalan H, Bardelli A., Kinzler, K.W., Vogelstein B., and Velculescu V.E.
  RAF/RAS oncogenes and mismatch-repair status.
  (2002) Nature, 418:934
• Bardelli A, Cahill D., Lederer G., Speicher M., Kinzler K., Vogelstein B. and Lengauer C.
  Carcinogen-Specific Induction of Genetic Instability.
  (2001) Proceedings of The National Academy Of Sciences 98(10) 5770-5775
• Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St Croix B., Romans K.E., Choti M.A., Lengauer C., Kinzler K.W., and Vogelstein A.
  Phosphatase Associated With Metastasis of Colorectal Cancer.
  (2001) Science. 9;294:1343-6.